Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Genesis is entitled to receive $35m in upfront payment for three targets.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
As mpox spreads, ‘national governments have a moral responsibility to help’
Combating ÎÛÎÛÂþ®‹ Crime with On-Dose Authentication
Syntekabio and Enamine partner for AI-based drug development
Novavax wins FDA emergency approval for updated Covid-19 vaccine